| Literature DB >> 28007659 |
Sergo Vashakidze1, Albert Despuig2, Shota Gogishvili1, Keti Nikolaishvili1, Natalia Shubladze1, Zaza Avaliani1, Nestan Tukvadze1, Martí Casals3, Joan A Caylà3, Pere-Joan Cardona2, Cristina Vilaplana4.
Abstract
OBJECTIVES: Our aim was to retrospectively compare clinical data and characteristics of removed lesions of the cohort of patients undergoing therapeutical surgery for their tuberculosis. DESIGN AND METHODS: Demographic and epidemiological details, clinical data, data on the surgery performed, macroscopic characteristics of the TB lesions removed, and outcome were recorded retrospectively from the 137 patients who underwent therapeutical surgery for their TB in Tbilisi, Georgia during 2014 and 2015.Entities:
Keywords: DS-TB; Gender; MDR/XDR-TB; Necrosis; Surgery; Tuberculosis
Mesh:
Substances:
Year: 2016 PMID: 28007659 PMCID: PMC5660856 DOI: 10.1016/j.ijid.2016.12.009
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Data recorded
| Group | Category | Variables |
|---|---|---|
| Demographic and epidemiological data | Age (years old) | In years old |
| Gender | Male/Female | |
| Smoking habit | on daily or almost daily basis, weekly, monthly, less than monthly, never | |
| Alcohol intake | on daily or almost daily basis, weekly, monthly, less than monthly, never | |
| General clinical data | Presence of comorbidities | Diabetes mellitus, HIV infection, immunosupression other than HIV-infection, renal failure, chronic obstructive pulmonary disease (COPD) previous to TB, Hepatitis C Virus infection, hepatic cirrosis, others |
| Clinical data regarding the TB | history of previous treatment | new patient, relapse patient: treatment after failure, treatment after loss to follow-up patient, other previously treated patient, unknown previous TB treatment |
| anatomical site of TB | Pulmonary, extrapulmonary | |
| drug-sensitivity | Drug Sensitive (DS-TB), Rifampicin Resistant only, Monoresistance to any other drug other than rifampicin, polydrug resistance, MultiDrug Resistant (MDR), extradrug resistance (XDR) | |
| date of diagnosis of the present TB episode | dd/mm/yy | |
| date of treatment initiation | dd/mm/yy | |
| number of lesions found in the chest X-ray assay | n | |
| bacteriology cured or not at the time of surgery according to WHO’s guidelines | Yes/No | |
| time in negativization of culture | Recorded in months, and analyzed as always negative, negative at ≤2 months (M) or negative at >2 M | |
| time from TB diagnosis and surgery | In days | |
| Data regarding the surgery performed | main indication for surgery | Still lesions in X-ray assays, Clinically not cured, Microbiologically not cured, Others (spontaneous pneumothorax, pulmonary haemorrhage, pleural empiema) |
| number of operated lesions | n | |
| type of surgery performed | segmentectomy (for lesion resection or removing lung segment), lobectomy (for lung resection or removing lung lobe), Pulmonectomy (for removal of the whole lung) | |
| date of surgery | dd/mm/yy | |
| post-surgery complications | Open answer | |
| Data on macroscopical characteristics of the TB lesions removed (surgical specimens) | lesion size | in cm, considering the maximum lenght |
| type of lesion operated | tuberculoma, cavitation | |
| presence of necrosis | no necrosis, necrosis: moderate growth of connective tissue, alternating with unmodified lung tissue, cirrosis: complete substitution of lung tissue by the connective tissue with damage of vessels and bronchies | |
| type of necrosis | fresh: necrosis macroscopically looking like of a liquid consistency, dry: necrosis macroscopically looking like of a dry consistency, both: coexistence of fresh and dry necrosis | |
| Presence of Acid Fast Bacilli (AFB) | Yes/No | |
| Positivity of culture of samples in solid medium (Lowenstein-Jensen) for | Yes/No | |
| Outcome | Official final outcome according to WHO definitions | Treatment completed, Treatment success, Cured, Lost of follow-up, Treatment failed, Still not known, Not evaluated, Death (if death, date of death in dd/mm/yy recorded) |
Distribution of tuberculosis patients by drug-resistance according to WHO classification.
| Drug-Resistance (WHO) | TOTAL | Males | Females | ||
|---|---|---|---|---|---|
|
|
| ||||
| N | % | N | % | ||
| DS-TB | 78 | 54 | 69.23 | 24 | 30.76 |
| monoR | 2 | 2 | 100 | 0 | 0 |
| Rifampicin only | 2 | 2 | 100 | 0 | 0 |
| MDR/XDR-TB | 55 | 38 | 69.09 | 17 | 30.09 |
| MDR-TB | 42 | 33 | 78.57 | 9 | 21.42 |
| XDR-TB | 13 | 5 | 38.46 | 8 | 61.53 |
Abbreviations: WHO: World Health Organization; DS-TB: Drug-Sensitive Tuberculosis; monoR: mono Resistant; MDR/XDR-TB: Multi Drug-Resistant/Extensively Drug-Resistant Tuberculosis.
Figure 1Time in sputum culture conversion.
Time to sputum culture conversion (always negative, less than 2 months (≤2 months) and more than 2 months (>2 months)) is represented in percentages, for DS-TB and MDR/XDR-TB cases. Total values and results stratified by gender (males (of more or less than 43 years old) and females) are graphically represented.
Days between diagnosis and surgery date.
| Drug-Resistance (WHO) | Median (25% – 75%) | ||
|---|---|---|---|
|
| |||
| TOTAL | Males | Females | |
| All patients | 233 (100 – 252.5) | 208.5 (50.5 – 344) | 263 (210 – 373.5) |
| DS-TB | 178.5 (38.25 – 258.75) | 81.5 (17.5 – 225.25) | 225.5 (192.5 – 275) |
| MDR/XDR-TB | 351 (233 – 455) | 308.5 (215.75 – 405.5) | 373 (266.5 – 654) |
| MDR-TB | 305.5 (232 – 399.75) | 307 (225 – 400.5) | 304 (237 – 511) |
| XDR-TB | 532 (276 – 666) | 454 (166 – 610) | 533 (372.25 – 891.5) |
Abbreviations: WHO: World Health Organization; DS-TB: Drug-Sensitive Tuberculosis; monoR: mono Resistant; MDR/XDR-TB: Multi Drug-Resistant/Extensively Drug-Resistant Tuberculosis.
All patients include: mono resistant, rifampicin only resistant, DS-TB and MDR/XDR-TB patients.
Statistically significant differences between males and females, p = 0.0037.
Statistically significant differences between DS-TB Males and DS-TB females, p = 0.0002.
Statistically significant differences between TOTAL DS-TB and TOTAL MDR/XDR-TB, p <0.0001.
Statistically significant differences between DS-TB males and MDR/XDR-TB males, p <0.0001.
Statistically significant differences between DS-TB females and MDR/XDR-TB females, p = 0.0005.
Figure 2Necrosis type found in lesions.
Percentages of presence of the different type of necrosis (fresh, dry and both) are represented for DS-TB and MDR/XDR-TB cases. Total values and results stratified by gender (males (of more or less than 43 years old) and females) are graphically represented.
Figure 3Types of necrosis in surgical specimens.
Macroscopic photographs of removed surgical specimens showing fresh necrosis (A), both fresh and dry necrosis (B) and dry necrosis (C).
Percentage of AFB and culture positive in samples from surgical specimens.
| TOTAL | Lesions in X-Ray | Cavities and tuberculomas | WHO Bacteriologically Cured | Samples from surgical specimens | ||
|---|---|---|---|---|---|---|
|
| ||||||
| AFB + | Culture + | |||||
| Characteristics according to Drug-resistance | ||||||
| DS-TB | 78 | 51 (65.38%) | 51 (100%) | 50 (98.04%) | 28 (56%) | 7 (14%) |
| MDR/XDR-TB | 55 | 47 (85.45%) | 47 (100%) | 47 (100%) | 31 (65.96%) | 11 (23.40%) |
| Characteristics according to gender | ||||||
| Males >43 years old | 48 | 29 (60.42%) | 29 (100%) | 28 (96.55%) | 19 (67.86%) | 3 (10.71%) |
| Males ≤43 years old | 48 | 34 (70.83%) | 34 (100%) | 34 (100%) | 19 (55.88%) | 6 (17.65%) |
| Females | 41 | 38 (92.68%) | 38 (100%) | 38 (100%) | 23 (60.53%) | 9 (23.68%) |
| Characteristics according to type of necrosis | ||||||
| Fresh necrosis | 88 | 70 (79.55%) | 70 (100%) | 70 (100%) | 41 (58.57%) | 15 (21.43%) |
| Dry necrosis | 8 | 6 (75%) | 6 (100%) | 6 (100%) | 5 (83.33%) | 0 |
| Both | 27 | 23 (85.18%) | 23 (100%) | 22 (95.65%) | 15 (68.18%) | 3 (13.64%) |
| Characteristics according to negativization time | ||||||
| Always negative | 43 | 15 (34.88%) | 15 (100%) | 14 (93.33%) | 9 (64.28%) | 5 (35.71%) |
| ≤2 months | 71 | 68 (95.77%) | 68 (100%) | 68 (100%) | 42 (61.76%) | 9 (13.23%) |
| >2 months | 23 | 18 (78.26%) | 18 (100%) | 18 (100%) | 10 (55.55%) | 4 (22.22%) |
Abbreviations: WHO: World Health Organization; AFB: Acid Fast Bacilli; DS-TB: Drug-Sensitive Tuberculosis; MDR/XDR-TB: Multi Drug-Resistant/Extensively Drug-Resistant Tuberculosis.